Prediabetes
Conditions
Brief summary
Prediabetes is an intermediate transition to hyperglycemia between normal blood glucose and diabetes, including impaired fasting glucose (IFG), impaired glucose tolerance (IGT)and the presence of a combination of the two. At present, the prediabetes population in China is very large. Timely detection of this sub-health population and effective intervention are the key to prevent or delay diabetes and related complications. Basic research showed that Tangningtongluo had a good hypoglycemic effect on db/db diabetic mice and STZ induced diabetic rats, and could alleviate pancreatic islet destruction and insulin resistance to some extent. In this study, the therapeutic effects of Tangningtongluo pian provided by Guizhou bailing Enterprise Group Pharmaceutical Co., Ltd on patients with prediabetes was evaluated clinically. A multi-center, randomized, double-blind, placebo-controlled clinical trial was designed to provide evidence-based medical evidence for Tangningtongluo pian in the treatment of prediabetes . In the design of this trial, the therapeutic effects and safety of Tangningtongluo pian in the treatment of prediabetes were evaluated with Tangningtongluo pian in the treatment group and placebo in the control group.
Detailed description
Prediabetes is an intermediate transition to hyperglycemia between normal blood glucose and diabetes, including impaired fasting glucose (IFG), impaired glucose tolerance (IGT)and the presence of a combination of the two. At present, the prediabetes population in China is very large. Timely detection of this sub-health state and effective intervention are the key to prevent or delay diabetes and related complications. Prediabetes is mainly IGT, and its core pathophysiological basis is insulin resistance. The existing western medicine can improve insulin resistance to varying degrees, but it can not prevent diabetes. Tangning Tongluo is an in-hospital preparation of Guizhou bailing. It is used for diabetes caused by deficiency of Qi and Yin. The symptoms include thirst, drinking, overeating, polyuria, weight loss, shortness of breath, fatigue, hand, foot and heart heat and blurred vision; Type 2 diabetes and diabetic retinopathy see the above syndrome.Basic research showed that Tang Ning Tong Luo had a good hypoglycemic effect on db/db diabetic mice and STZ induced diabetic rats, and could alleviate pancreatic islet destruction and insulin resistance to some extent. In addition, the drug has a certain retarding effect on diabetic nephropathy animal models \[renal function, renal pathology, urinary protein (3+ to 2+)\] and fundus lesions, and also improves liver function and myocardial enzymes. Further mechanism studies show that Tangning Tongluo exerts its anti-inflammatory, hypoglycemic and obesity induced insulin resistance effects by up regulating the expression of sequence binding protein (SBP) 2 in macrophages ; In addition, mip1 was inhibited γ/ CCR1 axis improves in diabetic retinopathy.It is speculated that the drug may be effective for prediabetes In this study, the therapeutic effects of Tangningtongluo pian provided by Guizhou bailing Enterprise Group Pharmaceutical Co., Ltd on patients with prediabetes was evaluated clinically. A multi-center, randomized, double-blind, placebo-controlled clinical trial was designed to provide evidence-based medical evidence for Tangningtongluo pian in the treatment of prediabetes . In the design of this trial, the therapeutic effects and safety of Tangningtongluo pian in the treatment of prediabetes were evaluated with Tangningtongluo pian in the treatment group and placebo in the control group.
Interventions
Tangningtongluo Tablet is an in-hospital preparation of Guizhou bailing. It is used for diabetes caused by deficiency of Qi and Yin. The symptoms include thirst, drinking, overeating, polyuria, weight loss, shortness of breath, fatigue, hand, foot and heart heat and blurred vision; Type 2 diabetes and diabetic retinopathy see the above syndrome. The present study shows that Tangningtongluo Tablet have certain hypoglycemic effects in diabetic animal models and diabetic patients, and may improve insulin sensitivity in diabetic mice.It is speculated that the drug may be effective for prediabetes. (0.4g/tablet,Plate(12 pills/plate ×3 plates/box))
BEHAVIORALlifestyle intervention
Avoid overeating, avoid large intake of high-calorie, high-fat foods, live a regular life, avoid sitting for a long time, strengthen exercise and reduce weight.
Sponsors
Beijing University of Chinese Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* FPG 5.6mmol/L\ 6.9mmol/L or OGTT 2H blood glucose 7.8mmol/L\ 11.0mmol/L or HbA1c 5.7%\ 6.4%, the above 3 indicators need to meet at least 2 items； * Age 18 \ 70 years old (including boundary value); * Patients who voluntarily signed the informed consent and had conditional follow-up.
Exclusion criteria
* Regularly take drugs affecting blood glucose within 1 month before screening, such as hypoglycemic drugs, glucocorticoids, niacin β- Adrenergic agonists, thyroid hormones, contraceptives, diazoxide, diuretics, phenytoin sodium γ- Interferon, etc; * Combined with various diseases that may significantly shorten life expectancy, such as malignant tumors, severe organ failure and so on; * Combined with various diseases that may seriously affect the subject's participation in the test, such as psychosis, serious motor system abnormalities, etc; * Combined ALT or ast \> 2.5 times the upper limit of normal value, or serum creatinine \> 1.5mg/dl; * Allergic to the test drug or its components; * Pregnant or lactating women, or women who have pregnancy plans from the study period to 3 months after the last administration, or men who are unwilling to take a medically recognized effective non drug contraceptive measure. * Chronic diarrhea caused by inflammatory bowel disease and irritable bowel syndrome; * The investigator believes that it is inappropriate to be included in this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Inflammatory factor index: FGF-21 | Baseline, 12weeks, 24weeks(if necessary) | Changes of FGF-21 from baseline |
| Inflammatory factor index: hsCRP | Baseline, 12weeks, 24weeks(if necessary) | Changes of hsCRP from baseline |
| Insulin sensitivity index | Baseline, 12weeks, 24weeks(if necessary) | The change of Matsuda index value from baseline calculated according to three-point OGTT (0, 30min, 120min). |
| Pancreatic β-cell function indicators | Baseline, 12weeks, 24weeks(if necessary) | The change of Pancreatic β-cell function indicators from baseline according to insulin source index and insulin disposal index. |
| HbA1c | Baseline, 12weeks, 24weeks(if necessary) | The change of HbA1c from baseline |
| Metabolic index | Baseline, 12weeks, 24weeks(if necessary) | Changes of fasting blood glucose, OGTT 2H blood glucose,body weight, BMI, waist circumference, waist hip ratio, blood lipid (TC, TG, HDL-C, LDL-C), free fatty acid and blood uric acid from baseline |
| Diabetes incidence rate | Baseline, 12weeks, 24weeks(if necessary) | Diabetes incidence rate of experimental group=Number of people diagnosed with diabetes/The sample size of experimental group Diabetes incidence rate of placebo group=Number of people diagnosed with diabetes/The sample size of placebo group |
| The rate of blood glucose reversed to normal | Baseline, 12weeks, 24weeks(if necessary) | The rate of blood glucose reversed to normal in experimental group=Number of people blood glucose reversed to normal/The sample size of experimental group The rate of blood glucose reversed to normal in placebo group=Number of people blood glucose reversed to normal/The sample size of placebo group |
| Changes in the proportion of subjects diagnosed with fatty liver from baseline | Baseline, 12weeks, 24weeks(if necessary) | Changes in the proportion of the experimental group=The proportion of subjects diagnosed with fatty liver after treatment in the experimental group-The proportion of subjects diagnosed with fatty liver in the experimental group in baseline； Changes in the proportion of the placebo group=The proportion of subjects diagnosed with fatty liver after treatment in the placebo group-The proportion of subjects diagnosed with fatty liver in the placebo group in baseline； |
| Vascular endothelial function indexes: PAI-1 | Baseline, 12weeks, 24weeks(if necessary) | Changes of PAI-1 from baseline |
| Vascular endothelial function indexes: NO | Baseline, 12weeks, 24weeks(if necessary) | Changes of NO from baseline |
| Vascular endothelial function indexes: ET-1 | Baseline, 12weeks, 24weeks(if necessary) | Changes of ET-1 from baseline |
| Inflammatory factor index: TNF-α | Baseline, 12weeks, 24weeks(if necessary) | Changes of TNF-α from baseline |
| Inflammatory factor index: IL-6 | Baseline, 12weeks, 24weeks(if necessary) | Changes of IL-6 from baseline |
| Inflammatory factor index: IL-2 | Baseline, 12weeks, 24weeks(if necessary) | Changes of IL-2 from baseline |
| Inflammatory factor index: IL-1β | Baseline, 12weeks, 24weeks(if necessary) | Changes of IL-1β from baseline |
| Inflammatory factor index: adiponectin | Baseline, 12weeks, 24weeks(if necessary) | Changes of adiponectin from baseline |
| Urinary albumin creatinine ratio (UACR) | Baseline, 12weeks, 24weeks(if necessary) | Changes of Urinary albumin creatinine ratio (UACR) from baseline |
| Incidence of diabetic retinopathy | Baseline, 12weeks, 24weeks(if necessary) | Incidence of diabetic retinopathy of experimental group=Number of people diagnosed with diabetic retinopathy/The sample size of experimental group Incidence of diabetic retinopathy of placebo group=Number of people diagnosed with diabetic retinopathy/The sample size of placebo group |
| Carotid artery intima-media thickness | Baseline, 12weeks, 24weeks(if necessary) | Changes of Carotid artery intima-media thickness measured by an ultrasound scanner from baseline |
| The scores of prediabetes symptom questionnaire | Baseline, 12weeks, 24weeks(if necessary) | Changes of the score of prediabetes symptom questionnaire from baseline . This scale is self-made and includes 15 symptoms. Each symptom scores 0-3 points, and the total score is 45 points. The higher the score, the more severe the symptoms. |
| The scores of short form health survey (SF-36) | Baseline, 12weeks, 24weeks(if necessary) | Changes of the MOS 36 item short form health survey (SF-36) scores from baseline，the minimum and maximum values of the survey are 156 and 37 respectively, and higher scores mean a better outcome. |
Countries
China
Contacts
Primary ContactMei Han
Outcome results
None listed